
## Tricyclic Analogues of Artemisinin: Synthesis and Antimalarial Activity of (+)-4,5-Secoartemisinin and (-)-5-Nor-4,5-secoartemisinin


## Mitchell A. Avery,\* "Wesley K. M. Chong," and James E. Bupp

<sup>a</sup> Department of Chemistry, Box 7185, University of North Dakota, Grand Forks, North Dakota 58202, USA
<sup>b</sup> Bio-organic Chemistry Laboratory, Life Sciences Division, SRI International, 333 Ravenswood Avenue, Menlo Park, California 94025, USA

Two ring-A cleaved analogues of the natural product artemisinin have been synthesized and examined for *in vitro* antimalarial activity.

The sesquiterpene (+)-artemisinin<sup>1</sup> 1 has been shown to possess significant antimalarial activity against drug-resistant strains of *Plasmodium falciparum*.<sup>2</sup> Since quantities of 1 are limited, considerable synthetic effort has been expended in total syntheses<sup>3–5</sup> and related model studies.<sup>6,7</sup> In addition, the search for analogues of 1 having superior pharmacological properties has culminated in studies of the 1,2,4-trioxane ring system,<sup>8,9</sup> the essential pharmacophore of 1, as well as dihydroartemisinin<sup>10</sup> and derivatives thereof.<sup>11–13</sup> Interesting additions to artemisinin structure-activity relationships (SAR) have been reported, including desethanoqinghaosu,<sup>13</sup> 9-desmethyl,<sup>5</sup> and 6,9-desmethylartemisinin,<sup>14</sup> 10-deoxoartemisinin<sup>15</sup> and 8*a*,9-secoartemisinin.<sup>16</sup>






Scheme 1 Reagents and conditions: i,  $B_2H_6$ , tetrahydrofuran;  $H_2O_2$ , NaOH; ii, Bu<sup>t</sup>Me<sub>2</sub>SiCl, 4-*N*,*N*-dimethylaminopyridine, CH<sub>2</sub>Cl<sub>2</sub>; iii, (COCl)<sub>2</sub>, dimethyl sulphoxide; Et<sub>3</sub>N; iv, lithium diisopropylamide, tetrahydrofuran, -78 °C; then MeI; v, MeO(Me)<sub>2</sub>SiCHLiSiMe<sub>3</sub> 6, pentane; vi, Bu<sup>n</sup><sub>4</sub>NF, tetrahydrofuran; vii, pyridinium dichromate, *N*,*N*-dimethylformamide; viii, O<sub>3</sub>-O<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, -78 °C; then acetaldehyde, Amberlyst-15, 22 °C; ix, O<sub>3</sub>-O<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, -78 °C; then acetaldehyde,

We report the synthesis of (-)-5-nor-4,5-secoartemisinin 2 ('desmethanoqinghaosu'), and (+)-4,5-secoartemisinin 3. It is expected that these analogues will provide useful information regarding the effects on activity of different relative orientations of the peroxy grouping compared to that in 1. Furthermore, it is hoped that the methodology described herein can be advantageously employed in an alternative total synthetic route to the natural product 1.

The analogues 2 and 3 were synthesized from (-)-isopulegol 4 as shown in Scheme 1. Hydroboration of naturally derived 4 gave the known diol 5 in 80% yield.<sup>17</sup> Selective silylation of the primary hydroxy group of 5 with t-butyldimethylsilyl chloride in the presence of 4-dimethylaminopyridine<sup>18</sup> proceeded successfully to give 7, which then underwent Swern oxidation to provide the ketone 8 in 75% overall yield. Kinetic deprotonation of this ketone went smoothly to afford regioisomerically pure enolate as evidenced by quenching with methyl iodide to furnish a single product 9, in acceptable yield.

The recent finding that (dimethylmethoxysilyl)trimethylsilylmethyllithium 6 undergoes additions to simple unhindered ketones to afford trimethylsilylalkenes<sup>19</sup> allowed for a different approach than that which we had previously used to construct our vinyl silanes.<sup>5,14,20</sup> Thus, treatment of the ketones 8 or 9 with 6 in pentane furnished the requisite vinyl silanes 10 and 11 in reasonable yields. The by-product in these reactions consisted mainly of recovered ketone starting materials indicating that, in addition to Peterson alkenation,



**Fig. 1** Perspective drawing of  $C_{15}H_{24}O_5$ . Non-hydrogen atoms are represented by thermal vibration ellipsoids drawn to encompass 50% of their electron density; hydrogen atoms are represented by arbitrarily small spheres that are in no way representative of their true thermal motion

these hindered ketones also underwent deprotonation. Next, the ketones were sequentially deprotected with tetrabutylammonium fluoride in tetrahydrofuran to provide the alcohols 12 and 13, which were then oxidized to the corresponding acids 14 and 15 with pyridinium dichromate in dimethylformamide.

As in preceding syntheses, we depended on the penultimate ozonolysis of a vinyl silane for introduction of the labile  $\alpha$ -hydroperoxyaldehyde moiety required for final construction of the trioxane ring. Hence, exposure of either acid 14 or 15 to ozone in dichloromethane at low temperature followed by warming and addition of acetone and Amberlyst-15 (acid source) led to the production of the targets 2 and 3 in good yield.<sup>†</sup> Proof for the structure 3 was obtained by single crystal X-ray crystallographic analysis as shown in Fig. 1.<sup>‡</sup> The structure 2 was deduced in the following way. The structure of the known analogue desethanoqinghaosu 16 was previously determined by X-ray crystallography. Submission of the acid

<sup>†</sup> For 2, m.p. 109–110 °C;  $[\alpha]_D^{22}$  –94.5 (c 0.145, chloroform); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) at 22 °C; δ 1.01 (d, J 6.4 Hz, 6 H), 1.22 (br s, 3 H), 1.42 (br s, 2 H), 1.56 (s, 3 H), 1.64 (br s, 2 H), 1.83 (br s, 2 H), 1.94 (m, 1 H), 2.01 (br, 0.3 H), 2.68 (m, 0.7 H), 3.10 (br, 0.7 H), 3.55 (br, 0.3 H), 5.60 (br, 1 H). However, at -10°C, 2 displayed the following 7:3 mixture: δ 0.75 (m, 1 H), 0.99 (d, J 6.4 Hz, 1 H), 1.00 (d, J 6.4 Hz, 2 H), 1.19 (d, J 7.2 Hz, 2 H), 1.23 (d, J 7.3 Hz, 1 H), 1.41 (s, 2 H), 1.57 (s, 1 H), 1.64 (s, 2 H), 1.65 (s, 1 H), 1.82 (m, 2 H), 1.93 4.0, 13.5 Hz, 0.7 H), 3.10 (dq, *J* 5.1, 7.2 Hz, 0.7 H), 3.55 (dq, *J* 4.4, 7.3 Hz, 0.3 H), 5.61 (s, 0.7 H), 5.70 (s, 0.3 H). For **3**, m.p. 102–103 °C;  $[\alpha]_{D^{22}}$  +22.9 (c 0.520, dichloromethane); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) at 22 °C; δ 1.00 (d, J 6.4 Hz, 3 H), 1.05 (m, 1 H), 1.12 (d, J 6.7 Hz, 2 H), 1.24 (d, J7.2 Hz, 3 H), 1.41 (s, 3 H), 1.61 (s, 3 H), 1.77 (br, 1 H), 1.91 (br, 2 H), 3.72 (br, 1 H), 5.66 (s, 1 H). However, at -18 °C a single conformer of 3 was observed:  $\delta$  0.99 (d, J 6.4 Hz, 3 H), 1.04 (m, 2 H), 1.09 (d, J 7.2 Hz, 3 H), 1.20 (m, 1 H), 1.24 (d, J = 7.2 Hz, 3 H), 1.36 (m, 1 H), 1.40 (s, 3 H), 1.61 (s, 3 H), 1.75 (m, 1 H), 1.90 (m, 2 H), 3.72 (dq, J 4.6, 7.2 Hz, 1 H), 5.66 (s, 1 H). The result of X-ray crystallographic analysis of 3 (single crystal) is shown in Fig. 1.

<sup>‡</sup> Crystal data: C<sub>15</sub>H<sub>24</sub>O<sub>5</sub>, compound **3**, monoclinic, space group  $P2_1/n$ ,  $M_r = 284.35$ , a = 9.957(6), b = 9.212(10), c = 15.965(10) Å;  $\beta = 93.15(3)^\circ$ , U = 1462.10 Å3, Z = 4,  $D_m = 1.2918$ ,  $D_c = 1.292$  g cm<sup>-3</sup>, T = 158 K, 1567 observed data with  $F > 2.33\sigma$  (F), R = 0.034. Atomic coordinates, bond lengths and angles and thermal parameters have been deposited at the Cambridge Crystallographic Data Centre. See Notice to Authors, Issue No. 1.

14 to ozone as before, but with subsequent cyclization to acetaldehyde, afforded 16, thus establishing the stereochemistry of 14 and 2.

The analogues 2 and 3 have been tested *in vitro* against drugresistant strains of *P. falciparum* at the Walter Reed Army Institute of Research. The IC<sub>50</sub> values for these analogues ranged from 3 to 6 ng cm<sup>-3</sup> while the IC<sub>50</sub> for (+)-artemisinin was 0.2–0.8 ng cm<sup>-3</sup>. Interesting conformational effects have been displayed by some members of this class of antimalarial analogues of 1 and are being further examined by NMR, molecular modelling, and X-ray crystallography in order to understand better the relative activities of these analogues.<sup>21</sup>§ Further work in progress focuses on the extension of Scheme 1 to provide (+)-artemisinin, 1. As can be seen, if R in 14 were a 3-oxobutyl group, then the penultimate step (viii) would yield the natural product.

This work was funded by the U.S. Army Medical Research and Development Command (Contribution No. 1866) under Contract No. DAMD17-88-C-8007. We wish to thank MRDC staff, including Drs Engle, Milhous and Musallam, for their contributions, as well as Professor P. A. Grieco for assistance in obtaining X-ray data.

Received, 17th May 1990; Com. 0/02180F

§ Studies of a related analogue indicate that the minor conformational isomer observed at low temperature in chloroform solution (NMR) does not correspond exactly to the relative conformation of the natural product 1. While the peroxy ring is in a boat conformation, it is in a different boat conformation than artemisinin. The major solution conformer appears to be in an 'unnatural' chair-chair-chair conformation as was also seen in the X-ray structure determination of this analogue. Neither conformer overlaps well with the natural product. The antimalarial potency of these analogues is apparently attenuated by this lack of overlap.

## View Article Online

## References

- 1 Qinghaosu Research Group, Sci. Sin., 1980, 23, 380.
- 2 C. Shen and L. Zhuang, Med. Res. Rev., 1984, 4, 58.
- 3 G. Schmid and W. Hofheinz, J. Am. Chem. Soc., 1983, 105, 624.
- 4 X. Xu, J. Zhu, D. Huang and W. Zhou, Tetrahedron, 1986, 42, 818.
- 5 M. A. Avery, C. Jennings-White and W. Chong, Tetrahedron Lett., 1987, 28, 4629.
- 6 M. Jung, H. ElSohly, E. Croom, A. McPhail and D. McPhail, J. Org. Chem., 1986, 51, 5417; F. Binns and T. Wallace, Tetrahedron Lett., 1989, 30, 1125.
- 7 G. Clark, M. Nikaido, C. Fair and J. Lin, J. Org. Chem., 1985, 50, 1994.
- 8 J. Kepler, A. Philip, Y. Lee, M. Morey and F. Carroll, J. Med. Chem., 1988, 31, 713.
- 9 C. Jefford, J. Boukouvalas, S. Kohmoto and G. Bernardinelli, *Tetrahedron*, 1985, **41**, 2081; J. Boukouvalas, *Helv. Chim. Acta*, 1986, **69**, 1778.
- 10 X. Lou and C. Shen, Medicinal Research Rev., 1987, 7, 29.
- 11 A. Brossi, B. Venugopalan, L. Dominquez Gerpe, H. Yeh, J. Flippen-Anderson, P. Buchs, X. Luo, W. Milhous and W. Peters, J. Med. Chem., 1988, 31, 645.
- 12 N. Acton and D. Klayman, Planta Medica, 1987, 266.
- 13 Y. Imakura, T. Yokoi, T. Yamagishi, J. Koyama, H. Hu, D. McPhail, A. McPhail and K. Lee, J. Chem. Soc., Chem. Commun., 1988, 372.
- 14 M. A. Avery, W. Chong and C. Jennings-White, J. Org. Chem., 1989, 54, 1792.
- 15 M. Jung, X. Li, D. Bustos, H. ElSohly and J. McChesney, *Tetrahedron Lett.*, 1989, 30, 5973.
- 16 M. A. Avery, W. Chong and G. Detre, *Tetrahedron Lett.*, 1990, 31, 1799.
- 17 K. Shulte-Elte and G. Ohloff, Helv. Chim. Acta, 1967, 50, 153.
- 18 S. Chaudhary and O. Hernandez, Tetrahedron Lett., 1979, 2, 99.
- 19 T. Bates and R. Thomas, J. Org. Chem., 1989, 54, 1784.
- 20 M. A. Avery, C. Jennings-White and W. Chong, J. Org. Chem., 1989, 54, 1789.
- 21 W. Inman, M. Avery, W. Chong and P. Crews, J. Org. Chem., submitted for publication.